Genesis Molecular AI vs Iktos (2026)
Both build small molecule design platforms that their own chemists and their partners use. Genesis Molecular AI, a Stanford spinout, runs GEMS: generative models for ideation, multitask models for absorption, distribution, metabolism and excretion, and agents that handle routine steps while chemists decide what to make. Its Pearl model, released in October 2025, predicts protein ligand structures and can be fine tuned on a program's own data. Iktos, founded in Paris in 2016, sells software directly: Makya for generative design with synthetic accessibility built in, Spaya for retrosynthesis, and engine APIs, alongside robotic chemistry and discovery collaborations. Genesis is mainly a partner; Iktos can also be bought as software your team runs.
- Pearl, a protein ligand structure model trained on proprietary physics based synthetic data and fine tunable on a program's data.
- Measured results with denominators against named baselines.
- Agents that orchestrate routine work while chemists keep the decisions.
- Generative design as software, Makya, with synthesis built into generation.
- Retrosynthesis with Spaya, routing to commercially available starting materials.
- Robotic synthesis, purification and testing, and APIs that plug the models into a team's own workflows.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Genesis Molecular AI and Iktos are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Genesis Molecular AI | Iktos |
|---|---|---|
| Primary category | Drug Discovery AI | Drug Discovery AI |
| Founded | 2019 | 2016 |
| Headquarters | Burlingame, CA | Paris, France |
| Website | genesis.ml | iktos.ai |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Stanford spinout, now trading as Genesis Molecular AI, building GEMS, a small molecule discovery platform its own chemists and its partners' programs run on. GEMS combines generative models for molecule ideation, multitask models for absorption, distribution, metabolism and excretion prediction, and agents that orchestrate routine steps while chemists interrogate predictions and decide what to synthesize.
Source: AI Health Index, September 2026
Iktos is a Paris generative AI and robotics company for small molecule drug discovery, founded in 2016. It sells two AI platforms: Makya, a generative design SaaS trained on millions of reactions that builds synthetic accessibility and a target product profile into generation (Makya 2.0 added a new analysis interface, and new ligand based 3D generative models arrived in January 2026), and Spaya, an AI retrosynthesis platform that finds routes to commercially available starting materials.
Source: AI Health Index, September 2026
Questions buyers ask
How are Genesis Molecular AI and Iktos priced and sold?
For Genesis Molecular AI, the engagement model is also described, with the company's engineers and drug hunters working inside partner teams. The per target fee exists but carries no figure, so the cost cannot be sized, and the headline values are what particular partners negotiated rather than a price anyone can apply.
Makya and Spaya are licensable software, with a demo request as the route in, and Iktos also runs discovery collaborations and its own pipeline; a strategic collaboration with Servier was reported at a potential value above €1 billion, which describes one negotiated deal rather than a price. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
How do Genesis Molecular AI and Iktos handle patient data?
In Genesis Molecular AI's case, the company's site carries no privacy policy, no terms of use and no data handling statement of any kind; the footer offers navigation and a contact page and nothing else.
For Iktos, no patient data is in the workflow. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
What evidence is published for Genesis Molecular AI and Iktos?
With Genesis Molecular AI, the evidence that can be checked is computational: the Pearl system's 78 percent success rate on 802 complexes from an outside consortium's public benchmark, reported against the six cofolding models and the docking methods that benchmark evaluated, in a zero shot setting with production settings and a post cutoff template.
In Iktos' case, the resources page lists the company's scientific publications and posters, including a 2026 paper on combining AI with human expertise to find PolQ inhibitors and work on compound selection guided by cell painting. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
How much do Genesis Molecular AI and Iktos leave to the clinician?
For Genesis Molecular AI, the platform's own account of the workflow puts the chemist at the decision: models generate candidates and predict properties, agents orchestrate the routine steps and surface trade-offs, and the chemist interrogates the predictions, visualizes the structures, filters and sorts, and decides what to synthesize.
Downstream, Iktos Robotics automates ordering, synthesis, purification, analysis and testing, and the company describes its direction as "fully autonomous labs". From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Drug Discovery AI page.
Both records were reviewed on this site in September 2026. Neither publishes prices, and part of Iktos's published material could not be read for this review.
Ask both how a designed molecule that fails synthesis or testing is fed back into the models.